Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirdametinib in advanced NF1-mutant melanoma
NCT07237100Phase 2Recruiting
- Start
- Oct 2025
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mirdametinib in melanoma. Started Oct 2025; status: recruiting.
02
Drugs
mirdametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07237100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07237100.